Lithuania vs Serbia: Statin use vs. average non-HDL cholesterol levels
Lithuania
3.7
in 2018
Serbia
3.7
in 2018
Lithuania rank
12th
Serbia rank
12th
Statin use vs. average non-HDL cholesterol levels over time
- Lithuania
- Serbia
How they compare
Lithuania currently reports 3.7 against 3.7 in Serbia, a difference of 0.
The two have swapped places 3 times across 39 shared years of data; in 1980 it was Lithuania ahead.
Lithuania ranks 12th and Serbia ranks 12th of 191 countries.
Across the 4 decades both report, Lithuania averaged higher in 2 and Serbia in 2.
Head to head by decade
| Decade | Lithuania | Serbia | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 4.6 | 4.17 | 0.43 | Lithuania |
| 1990s | 4.41 | 4.29 | 0.12 | Lithuania |
| 2000s | 4.09 | 4.1 | 0.01 | Serbia |
| 2010s | 3.83 | 3.86 | 0.0222 | Serbia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Lithuania or Serbia?
- Lithuania, at 3.7 against 3.7 in Serbia as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Lithuania and Serbia?
- 0, with Lithuania ahead.
- How many years of comparable data are there for Lithuania and Serbia?
- 39 years are reported by both, from 1980 to 2018.
- How do Lithuania and Serbia rank globally for statin use vs. average non-hdl cholesterol levels?
- Lithuania ranks 12th and Serbia ranks 12th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.